Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC

Wu, Fenglei; Hu, Nan; Yu, Li; Bian, Baoxiang; Xu, Gaixia; Zheng, Yi

doi:10.1007/s13402-012-0075-7

Cited by 19 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was confirmed by Boer et al [9]. Besides, another study showed that for rs4652 in galectin-3, the OS of NSCLC patients with an AA genotype is significantly longer than that of those with a CC genotype; furthermore, CC genotype carriers have a worse chemotherapy response and NSCLC prognosis [16], which is in accordance with the present study. The association of galectin-3 SNP rs11125 with beta-lactam allergy may be related to the binding of galectin-3 to immunoglobulin E (IgE) [21].…”

Section: Discussionsupporting

confidence: 92%

“…The presence of SNPs in relevant genes, their target binding sites, and processing machinery can affect cancer risk, patient prognosis, and treatment efficacy [15]. 1 study explored the correlation of galectin-3 SNPs with chemotherapy response and also the prognosis and treatment parameters of non-small cell lung cancer (NSCLC) [16]. It was verified that the SNP rs4644, coding for the protein galectin-3, affected galectin-3' susceptibility to cleavage by matrix metalloproteinases, providing guidance for future clinical therapy of breast cancer [17].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Correlations of Galectin-3 Gene Polymorphisms with Risk and Prognosis of Cervical Cancer in Chinese Populations: A Case-Control Study

Fang¹,

Feng²,

Li³

2017

Oncol Res Treat

View full text Add to dashboard Cite

Background: This study explores correlations of galectin-3 gene polymorphisms (rs4644, rs4652, and rs11125) with cervical cancer risk and prognosis in Chinese populations. Methods: A total of 126 patients with cervical cancer were selected to form the case group, and 102 healthy people were selected for the control group following a physical examination. 3 polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results: The distribution frequencies of the CC+CA genotype of rs4652 and the AT+TT genotype of rs11125 in the case group were remarkably higher than those in the control group. rs4644 only had correlations with tumor diameter, while rs4652 and rs11125 had correlations with tumor diameter, FIGO staging, differentiation grades, clinical staging, lymph node metastasis (LNM), and treatment modality. The 5-years survival rate of patients with CC+CA of rs4652 was lower but the recurrence rate was higher compared to AA type patients. In contrast, AA type patients with rs11125 had a higher 5-year survival rate but a lower recurrence rate than those of AT+TT type. CC+CA genotype of rs4652, AT+TT genotype of rs11125, and treatment modality were independent factors related to overall survival and disease-free survival, and LNM was an independent factor related to OS. Conclusion: Our findings provide evidence that allele C of rs4652 and allele T of rs11125 in the galectin-3 gene may be risk factors for cervical cancer.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Correlations of Galectin-3 Gene Polymorphisms with Risk and Prognosis of Cervical Cancer in Chinese Populations: A Case-Control Study

Fang¹,

Feng²,

Li³

2017

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…Patient responses to treatment were determined by the WHO criteria [18], which classify the response into four categories: complete response (CR), partial response (PR), stable disease (SD), and progressive disease [19]. CR and PR were combined as responders, and SD and PD were grouped as non-responders.…”

Section: Methodsmentioning

confidence: 99%

Notch 3 Protein, not its Gene Polymorphism, is Associated with the Chemotherapy Response and Prognosis of Advanced NSCLC Patients

Shi

Qian

et al. 2014

Cell Physiol Biochem

View full text Add to dashboard Cite

Aim: To study the relation of NOTCH3 and its gene polymorphisms with the chemotherapy response and the prognosis of patients with Non-small cell lung cancer (NSCLC). Methods: A total of 594 patients with advanced stage of NSCLC (IIIA, IIIB and IV) NSCLC were enrolled. All patients received Platinum-based chemotherapy. The NOTCH3 expression in tumors and its gene polymorphisms were determined. In vitro, several NSCLC cell lines received the NOTCH3 over-expression vector and small interfering RNA (siRNA) to study the role of NOTCH3 in regulation the cellular biological behaviors. Results: The genotype and the allele frequencies of NOTCH3 gene polymorphisms at 605C>T and 1735T>C were not significantly different between good responders and poor responders to chemotherapy. However, high NOTCH3 expression in tumor represented a significantly higher possibility of being resistant to chemotherapy. Also, patients with high NOTCH3 expression had a poorer prognosis than those with low NOTCH3 expression. In vitro studies showed that NOTCH3 inhibition dramatically suppressed the proliferation, migration, invasiveness abilities and prompted apoptosis in NSCLC cells. Conclusion: NOTCH3 regulates the cellular behavior, including, proliferation, marker to predict the chemotherapy response and prognosis of advanced NSCLC. marker to predict the chemotherapy response and prognosis of advanced NSCLC.

show abstract

“…All patients had received platinum-based chemotherapy after diagnosis (Table 1). The inclusion and exclusion criteria were described previously elsewhere [21]. The study was approved by the ethics committees of our hospital and written informed consent was obtained from each participant.…”

Section: Methodsmentioning

confidence: 99%

“…Patient responses to treatment were determined after four cycles by the WHO criteria [21], which classify the response into four categories: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). CR was defined as complete disappearance of all measurable lesions.…”

Section: Methodsmentioning

confidence: 99%

SIRT1 Expression Is Associated with the Chemotherapy Response and Prognosis of Patients with Advanced NSCLC

Zhang

Rong

Chen³

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

AimThe role of Sirtuin 1 (SIRT 1) in carcinogenesis is controversial. This study was to explore the association between the SIRT1 expression and the clinical characteristics, the responsiveness to chemotherapy and prognosis in Non-small cell lung cancer (NSCLC).MethodsWe enrolled 295 patients with inoperable advanced stage of NSCLC, namely, stage III (A+B) and IV NSCLC. All patients had received platinum-based chemotherapy after diagnosis and the chemotherapy response were evaluated. All patients were followed up for overall survival (OS) and progression free survival (PFS). In vitro, H292 cells were tranfected with SIRT1 small interfering RNA (siRNA). The cell biological behaviors and chemosensitivity to cisplatin treatment were studied. The in vivo tumorgenesis and metastasis assays were performed in nude mice.ResultsWe found that the SIRT1 expressions were significantly associated with the tumor stage, tumor size and differentiation status. Patients with high SIRT 1 expressions had a significantly higher chance to be resistant to chemotherapy than those with low SIRT 1 expression. Patients with high expression of SIRT1 had significantly shorter OS and DFS than those with low expression. Cox analyses confirmed that the SIRT 1 expression was a strong predictor for a poor OS and PFS in NSCLC patients underwent Platinum-based chemotherapy. In vitro studies revealed that the reduced expression SIRT 1 by siRNA technique significantly inhibited cell proliferation, migration and invasion. More importantly, SIRT1 si-RNA significantly enhanced the chemosensitivity of H292 cells to cisplatin treatment. The in vivo tumorgenesis and metastasis assays showed that SIRT1 knockdown dramatically reduced the tumor volume and the metastatic ability in nude mice.ConclusionCollectively, our data suggest that the SIRT1 expression may be a molecular marker associated with the NSLCLC clinical features, treatment responsiveness and prognosis of advanced NSCLC.

show abstract

Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC

Abstract: The galectin-3 genetic polymorphisms of galectin-3 +292, rather than galectin-3 +191, were associated with the chemotherapy response and prognosis of NSCLC.

Cited by 19 publications

References 27 publications

Correlations of <b><i>Galectin-3</i></b> Gene Polymorphisms with Risk and Prognosis of Cervical Cancer in Chinese Populations: A Case-Control Study

Correlations of <b><i>Galectin-3</i></b> Gene Polymorphisms with Risk and Prognosis of Cervical Cancer in Chinese Populations: A Case-Control Study

Notch 3 Protein, not its Gene Polymorphism, is Associated with the Chemotherapy Response and Prognosis of Advanced NSCLC Patients

SIRT1 Expression Is Associated with the Chemotherapy Response and Prognosis of Patients with Advanced NSCLC

Contact Info

Product

Resources

About